Genmab
2,056.00 DKK
+1.18 %
Less than 1K followers
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
+1.18 %
+11.29 %
+18.23 %
+42.23 %
+37.76 %
+32.73 %
-36.58 %
-12.73 %
+5,929.33 %
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
132.07B DKK
Turnover
173.9M DKK
Revenue
21.53B
EBIT %
31.14 %
P/E
16.82
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.2
2026
Annual report '25
19.3
2026
General meeting '26
7.5
2026
Interim report Q1'26
All
Research
Press releases
ShowingAll content types
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
